Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTR1D | P28221 | 4/20 | 0.53 |
| ▸ | HTR1B | P28222 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305515 | 0.89 | RAB9A (0.70) | RAB9ANPC1POLBHTR1DHTR1B | |
| SCHEMBL6308769 | 0.88 | NPC1 (0.60) | RAB9ANPC1POLBMAPK1HTR1D | |
| SCHEMBL6313054 | 0.85 | MAPT (0.61) | RAB9ANPC1POLBHTR1DHTR1B | |
| SCHEMBL6308941 | 0.84 | NPC1 (0.55) | RAB9ANPC1POLBMAPK1HTR1D | |
| SCHEMBL7812700 | 0.84 | HTR1A (0.57) | POLBMAPK1HTR1DHTR1BHTR1A | |
| SCHEMBL6308232 | 0.83 | RAB9A (0.55) | RAB9ANPC1POLBMAPK1HTR1D | |
| SCHEMBL6306100 | 0.83 | HTR1A (0.54) | POLBMAPK1HTR1DHTR1BHTR2A | |
| Hydrochloric Acid SCHEMBL6306223 | 0.83 | HTR1A (0.56) | POLBMAPK1HTR1DHTR1BHTR1A | |
| SCHEMBL6308881 | 0.82 | WDR5 (0.55) | RAB9ANPC1HTR1DHTR1BHTR2A | |
| SCHEMBL6306763 | 0.81 | HTR1A (0.57) | NPC1MAPK1HTR1DHTR1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | RAB9A 2881/4885NPC1 629/4885POLB 3767/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | RAB9A 2212/4885NPC1 955/4885POLB 2826/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | RAB9A 1827/4885NPC1 696/4885POLB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.